

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (withdrawn): A colon cancer transcriptional regulatory element (TRE) sequence, wherein said TRE is specific for metastatic colon cancer cells.

Claim 2 (withdrawn): The TRE sequence according to Claim 1, wherein said sequence is a human TRE sequence.

Claim 3 (withdrawn): The TRE sequence according to Claim 2, wherein said sequence is derived from a PRL-3 gene.

Claim 4 (withdrawn): The TRE sequence according to Claim 3, wherein said TRE is derived from the 0.6kb sequence upstream of the translational start codon for the PRL-3 gene, presented herein as SEQ ID NO:1.

Claim 5 (withdrawn): The TRE according to Claim 3, wherein said TRE is derived from the 1 kb sequence upstream of the translational start codon for the PRL-3 gene, presented herein as SEQIDNO:2.

Claim 6 (withdrawn): The TRE sequence according to Claim 3, wherein said TRE sequence has the sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, or a functional fragment thereof.

Claim 7-8 (cancelled)

Claim 9 (Currently amended): A replication-competent adenovirus vector comprising an adenovirus gene essential for replication under transcriptional control of a PRL-3 TRE prenylated protein tyrosine phosphatase 3 gene (PRL-3) transcriptional regulatory element (TRE) derived from wherein said sequence is obtained from the 0.6kb sequence upstream of the translational start codon for the PRL-3 gene, and has the transcriptional regulatory factor activity of the PRL-3 TRE sequence presented herein as SEQ ID NO:1.

Claim 10 (withdrawn): The adenovirus vector according to Claim 8, wherein said TRE is derived from the 1 kb sequence upstream of the translational start codon for the PRL-3 gene, presented herein as SEQ ID NO:2.

Claim 11 (Previously presented): The adenovirus vector according to claim 9, wherein said PRL-3 TRE comprises a human promoter or enhancer.

Claim 12 (Previously presented): The adenovirus vector according to claim 9, wherein said PRL-3 TRE further comprises a second human transcriptional regulatory factor response element.

Claim 13 (Previously presented): The adenovirus vector according to claim 9, wherein said PRL-3 TRE comprises a promoter and enhancer.

Claim 14 (Previously presented): The adenovirus vector according to claim 9, wherein said PRL-3 TRE comprises two or more enhancers.

Claim 15 (Previously presented): The adenovirus vector according to claim 9, wherein the adenoviral vector comprises first and second adenoviral genes co-transcribed under transcriptional control of said PRL-3 TRE.

Claim 16 (Currently amended): The adenovirus vector according to claim 15, wherein the second gene is under translational control of an [[IRES]] internal ribosome entry site (IRES).

Claim 17 (Previously presented): The adenovirus vector according to claim 9, wherein said adenoviral gene essential for replication is E1A or E1B.

Claim 18 (original): The adenovirus vector of Claim 17, wherein E1A or E1B has a mutation in or deletion of its endogenous promoter.

Claim 19 (Previously presented): The adenovirus vector of Claim 18, wherein E1B has a deletion of the 19-kDa region.

Claim 20 (Previously presented): A composition comprising:
a replication-competent adenovirus vector according to Claim 9 and a pharmaceutically acceptable excipient.

Claim 21 (Previously presented): An isolated host cell comprising the adenovirus vector of claim 9.